Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT07695701

Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

Conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis

Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Phase: PHASE4
Enrollment: 150
Sponsor: Eidos Therapeutics, a BridgeBio company

Location: Johns Hopkins University 056 Baltimore Maryland

Summary

The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

Eligibility Criteria

Key Inclusion Criteria: * Participants aged 18 to 80 * Confirmed diagnosis of ATTR-CM requiring targeted therapy * At screening: New York Heart Association (NYHA) Class I/II; estimated glomerular filtration rate (eGFR) ≥40 mL/min/1.73m2; left ventricular ejection fraction (LVEF) \>35%; left ventricular (LV) wall thickness ≥12 mm. * Heart failure condition has been clinically stable for at least 6 weeks prior to screening. Key Exclusion Criteria: * Current or planned implantation of a cardiac implantable electronic device (eg, pacemaker, implantable cardiac defibrillator). * Acute myocardial infarction, acute coronary syndrome or coronary revascularization, or experienced stroke or transient ischemic attack within 90 days prior to screening. * Hemodynamic instability. * Likely to undergo heart transplantation within 12 months from screening. * Confirmed diagnosis of AL amyloidosis at screening. * At screening: NYHA Class III/IV; National Amyloidosis Center (NAC) Stage 3. * Prior or current treatment with acoramidis.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07695701). StuddyBuddy aggregates publicly available trial information.